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I am in agreementwithDrsKorst and
Lee that there may be certain popula-
tions with nondysplastic Barrett’s
esophagus (BE) who may be at in-
creased risk for esophageal cancer.
There are currently no compelling
data, however, to recommend any inter-
vention beyond repeated surveillance
endoscopy in patients with BE. The
American Gastroenterological Associ-
ation based its recommendation for
surveillance on an estimated rate of
progression of disease to high-grade
dysplasia or adenocarcinoma of 0.5%.
Recent large, population-based studies
suggest that this risk estimate is actu-
ally too high. Hvid-Jensen and colle-
ages1 reported in the New England
Journal of Medicine in October 2011
an annual risk of progression to adeno-
carcinoma in patients with BE of
0.12%. This findingwas based on anal-
ysis of a comprehensive database that
included the entire population of Den-
mark. In a similar study of the entire
population of Northern Ireland, Bhat
and colleagues2 reported a nearly iden-
tical absolute annual risk of 0.13%.
Current data indicate that the risk to
the patient of malignant transformation
from BE is even lower than previously
thought, suggesting caution with inva-
sive strategies that may in fact be over-
treatment. There may be a role for
radiofrequency ablation in selected—
and currently undefined—subgroups
of patients with nondysplastic BE.The JournalGiven the overall low cancer risk, the
bar is set very high to prove cost-
effectiveness, reduction in cancer pro-
gression, or reduction in mortality.
I believe that radiofrequency ablation
for nondysplastic BE is therefore diffi-
cult to justify, outside of a well-
reasoned clinical trial.
Nirmal K. Veeramachaneni, MD
Division of Cardiothoracic Surgery
University of North Carolina–Chapel
Hill
Chapel Hill, NC
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EXTRACORPOREAL
MEMBRANE OXYGENATION IN
ACUTE RESPIRATORY
FAILURE: DOWE NEED A NEW
CONFIGURATION?
To the Editor:
We read with great interest the arti-
cle by Bonacchi and colleagues1 in
a recent issue of The Journal of Tho-
racic and Cardiovascular Surgery.
Bonacchi and colleagues1 presented
their experience with the use of veno-
venous extracorporeal membrane ox-
ygenation (ECMO) in 30 patients
with severe acute respiratory failure
and described their experience with
the use of a customized arterial can-
nula to reduce the blood recirculation
fraction (BRF) when high ECMO
flows are needed to improve systemic
oxygenation. In their ‘‘c’’ configura-
tion, a traditional inflow cannula is
modified by making a 60 angle in
its distal third to allow tip orientation
toward the tricuspid valve. In their se-
ries, Bonacchi and colleagues1 re-
ported significant improvements inof Thoracic and Cardiovascular Surgeoxygenation indices and a reduction
of more than 20% in the BRF. Impor-
tantly, the study showed that the mod-
ified cannula can be used safely
without mechanical complications.
The problem of recirculation with
a double-lumen catheter for venove-
nous ECMO has been well studied
in both animal and human models.2-4
In patients with acute respiratory
failure who require high ECMO
flow support, a low BRF is key to
ensure adequate systemic oxygen
delivery. The study by Bonacchi and
colleagues1 addresses this important
issue and demonstrates that a low
BRF is associated with successful ve-
novenous ECMO in patients with re-
spiratory distress. Although we
recognize the efforts of Bonacchi
and colleagues1 to develop a new
strategy to overcome the problem of
BRF when high ECMO flows are
needed, we would like to point out
several important points that they
failed to include in their report. First,
a bicaval dual-lumen catheter that is
already available in the United States
(Avalon Elite; Avalon Laboratories
LLC, Rancho Dominguez, Calif)
can be safely and successfully used
to provide adequate venovenous
ECMO support in patients with acute
respiratory failure.5 Second, the use
of this dual-lumen Avalon Elite can-
nula offers the advantage of single-
site cannulation, eliminates the need
to use multiple catheters, and avoids
the use femoral vascular access.5
Third, studies have shown that the
use of the dual-lumen Avalon Elite
cannula results in a very small BRF
(as low as 2%).6 Finally, placement
of the dual-lumen Avalon Elite can-
nula can be successfully achieved
with fluoroscopic and a transthoracic
echocardiographic guidance and does
not require an invasive transesopha-
geal approach.7
Although we applaud the efforts of
Bonacchi and colleagues1 and recog-
nize the value of their technique in
overcoming the problem of BRF, we
believe that the use of the currentlyry c Volume 143, Number 4 993
